IL	O
-	O
12	O
inhibition	O
of	O
endothelial	B-Cell
cell	I-Cell
functions	O
and	O
angiogenesis	O
depends	O
on	O
lymphocyte	B-Cell
-	O
endothelial	B-Cell
cell	I-Cell
cross	O
-	O
talk	O
.	O

In	O
vivo	O
IL	O
-	O
12	O
-	O
dependent	O
tumor	B-Cancer
inhibition	O
rests	O
on	O
the	O
ability	O
of	O
IL	O
-	O
12	O
to	O
activate	O
a	O
CD8	O
-	O
mediated	O
cytotoxicity	O
,	O
inhibit	O
angiogenesis	O
,	O
and	O
cause	O
vascular	B-Multi-tissue_structure
injury	O
.	O

Although	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
such	O
inhibition	O
stems	O
from	O
complex	O
interactions	O
of	O
immune	B-Cell
cells	I-Cell
and	O
the	O
production	O
of	O
IFN	O
-	O
gamma	O
and	O
other	O
downstream	O
angiostatic	O
chemokines	O
,	O
the	O
mechanisms	O
involved	O
are	O
still	O
poorly	O
defined	O
.	O

Here	O
we	O
show	O
that	O
IL	O
-	O
12	O
activates	O
an	O
anti	O
-	O
angiogenic	O
program	O
in	O
Con	O
A	O
-	O
activated	O
mouse	O
spleen	B-Cell
cells	I-Cell
(	O
activated	O
spc	B-Cell
)	O
or	O
human	O
PBMC	B-Cell
(	O
activated	O
PBMC	B-Cell
)	O
.	O

The	O
soluble	O
factors	O
they	O
release	O
in	O
its	O
presence	O
arrest	O
the	O
cycle	O
of	O
endothelial	B-Cell
cells	I-Cell
(	O
EC	B-Cell
)	O
,	O
inhibit	O
in	O
vitro	O
angiogenesis	O
,	O
negatively	O
modulate	O
the	O
production	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
,	O
and	O
the	O
ability	O
of	O
EC	B-Cell
to	O
adhere	O
to	O
vitronectin	O
and	O
up	O
-	O
regulate	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
expression	O
.	O

These	O
effects	O
do	O
not	O
require	O
direct	O
cell	B-Cellular_component
-	I-Cellular_component
cell	I-Cellular_component
contact	I-Cellular_component
,	O
yet	O
result	O
from	O
continuous	O
interaction	O
between	O
activated	O
lymphoid	B-Cell
cells	I-Cell
and	O
EC	B-Cell
.	O

We	O
used	O
neutralizing	O
Abs	O
to	O
show	O
that	O
the	O
IFN	O
-	O
inducible	O
protein	O
-	O
10	O
and	O
monokine	O
-	O
induced	O
by	O
IFN	O
-	O
gamma	O
chemokines	O
are	O
pivotal	O
in	O
inducing	O
these	O
effects	O
.	O

Experiments	O
with	O
nu	O
/	O
nu	O
mice	O
,	O
nonobese	O
diabetic	O
-	O
SCID	O
mice	O
,	O
or	O
activated	O
spc	B-Cell
enriched	O
in	O
specific	O
cell	B-Cell
subpopulations	O
demonstrated	O
that	O
CD4	B-Cell
(	I-Cell
+	I-Cell
)	I-Cell
,	O
CD8	B-Cell
(	I-Cell
+	I-Cell
)	I-Cell
,	O
and	O
NK	B-Cell
cells	I-Cell
are	O
all	O
needed	O
to	O
mediate	O
the	O
full	O
anti	O
-	O
angiogenetic	O
effect	O
of	O
IL	O
-	O
12	O
.	O

